We are monitoring the impact of COVID-19 on Non-Insulin Diabetes Therapies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7836
Share on
Share on

Global Non-Insulin Diabetes Therapies Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Type and Region- Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 7836
Pages: 175

Non-Insulin Diabetes Therapies Market Size (2021 to 2026)

The size of the Global Non-Insulin Diabetes Therapies Market revenue is expected to be growing at a CAGR of 5.6% from 2021 to 2026. The size of the market is estimated to grow USD 21.36 billion by 2026 from USD 16.26 billion in 2021.

Non-Insulin Diabetes Therapeutics are administered orally and are prescribed to the person when the body glucose levels are elevated and cannot be controlled by Diet and Exercise.

The major factors driving the growth of the market is the increase in the number of people affected by Diabetes Type 2. The figure for people who have diabetes is expected to rise to 642 million by 2040. The engagement of companies to find medicines with fewer side effects has contributed a lot to the growth of the market. Non-Insulin drugs, when injected into the body, helps the liver to produce Insulin. The Insulin market dominated previously, but the type of the Non-Insulin drug will soon be at the same level as Insulin Type drugs. The change in lifestyle and food habits is the cause of diabetes, and thus, they will push forward market growth.

The primary challenge for this market is to produce drugs that have fewer side effects and are more effective than the currently used drugs. The benefits of these drugs are still unknown to many, so less awareness is also a challenge. The availability of these drugs to all people classes is also a big challenge as diabetes is a common disease. The general awareness about the functioning and uses of drugs is not known to many, making people more aware is another challenge for this market. The market leaders in this segment are based in few regions only, and thus the market penetration of the drugs is not so much, which results in low sales and less awareness. The government initiatives about increasing people’s attention are not in huge numbers and thus restrict the growth of the market.

Impact of COVID-19 on the global non-insulin diabetes therapies market

The COVID-19 pandemic is a serious situation right now, and the increasing number of new positive cases is a cause for concern for the whole world. The coronavirus and its effects on the body are being studied by scientists and pharmaceutical companies worldwide. The coronavirus is found to affect severely people who have heart problems or are suffering from diabetes. Thus, the non-insulin drug market is expected to grow during the pandemic as people need to treat heir diabetes so that the coronavirus does not become a deadly catalyst severely affecting the body. The lockdown prevented the supply and demand from being at the same level, and thus this gap between supply and demand is still needed to be filled. The lockdown also affected the movement of people, and the patients who have diabetes were not able to see their doctor, thus hampering the growth of the market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Drug Type and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (China), Mannkind (California), Bristol-Myers Squibb (New York), AstraZeneca (U.K), Boehringer Ingelheim (Germany) and Bayer (Germany).

 

This research report on the Global Non-Insulin Diabetes Therapies Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2026.

Non-Insulin Diabetes Therapies Market – By Drug Type:

  • Sulphonylureas     
  • Amylin Agonists    
  • GLP-1 Agonists & Analogs
  • Biguanides             
  • Glinides & Meglinitides      
  • Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
  • Thiazolidinediones (or Glitazones or TZDs 
  • Alpha-Glucosidase Inhibitors         
  • Dipeptidyl Peptidase-4 (DPP4) Inhibitors

The SGLT-2 inhibitors segment is expected to witness robust growth during the forecast period based on the drug type. The main reason contributing to growth is the minimum side effects of these drugs. These drug types are also very efficient as monotherapy or combination therapy. More detailed research is being carried out to find a new and efficient type of molecule. During the forecast period, Novartis and Ionis Pharmaceuticals products are the significant pipelines SGLT 2 inhibitors are in the process of a clinical study and is expected to launch during the forecast period.

 Biguanides drug type is currently in a shallow position in terms of market share but is expected to grow at a reasonable rate during the forecast period. These drugs work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for diabetes treatment. Thus set up of new companies and an effective supply chain will ensure the growth of this sub-segment.

Non-Insulin Diabetes Therapies Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America had the largest market share in 2020 and is expected to grow with a healthy rate during the forecast period. The increasing prevalence of diabetes is the primary factor supporting the growth rate. The other reasons propelling the market are many ongoing clinical trials and the availability of improved treatment options and health care infrastructure. The presence of global players is going to affect the market positively.

Europe had the second largest market share in 2019 and is expected to grow with a healthy future rate. The increasing diabetes cases due to the prevalence of unhealthy lifestyles and the rising quality of healthcare facilities will support the positive growth of this region.

The Asia Pacific market is expected to grow at the fastest rate among other regions. China has more diabetic patients than any other country globally, surpassing India, in the recent past. In India, about 62 million people are facing problems related to Diabetics. About 80 thousand deaths are expected to occur in America because of diabetes, and recent studies show us that around 1.4 million people have been diagnosed and treated for Type-2 Diabetes. The market is expected to increase exponentially in the coming years due to the rise in the number of people facing diabetic problems.

KEY MARKET PLAYERS:

Some of the key competitors participating in the Global Non-Insulin Diabetes Therapies Market profiled in this report are Tobira, Eli Lilly, and Sumitomo Dainippon Pharma, Novo Nordisk, Takeda, Sanofi, Mannkind, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Bayer.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 Sulphonylureas     

                                5.1.3 Amylin Agonists    

                                5.1.4 GLP-1 Agonists & Analogs

                                5.1.5  Biguanides             

                                5.1.6 Glinides & Meglinitides      

                                5.1.7 Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors              

                                5.1.8 Thiazolidinediones (or Glitazones or TZDs 

                                5.1.9 Alpha-Glucosidase Inhibitors          

                                5.1.10 Dipeptidyl Peptidase-4 (DPP4) Inhibitors

                                5.1.11 Y-o-Y Growth Analysis, By Drug Type        

                                5.1.12 Market Attractiveness Analysis, By Drug Type      

                                5.1.13 Market Share Analysis, By Drug Type        

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Product

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Tobira                           

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novo Nordisk                            

                8.3 Takeda                         

                8.4 Eli Lilly Sumitomo Dainippon Pharma                               

                8.5 Sanofi                           

                8.6 Mannkind                   

                8.7 Bayer                            

                8.8 Bristol Myers Squibb                              

                8.9 Astrazeneca                               

                8.10 Boehringer Ingelheim                          

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Drug, by  Region along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Global Non-Insulin Diabetes Therapy Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  3. Global Sulphonylureas Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Amylin Agonists Market, By Region, From 2021 to 2026 (USD Million)
  5. Global GLP-1 Agonists & Analogs Market, By Region, From 2021 to 2026 (USD Million)
  6. Global  Biguanides Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Alpha-Glucosidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Glinides or Meglitinides ! Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Thiazolidinediones or Glitazones or TZDs Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  13. North America Sulphonylureas Market, By Region, From 2021 to 2026 (USD Million)
  14. North America Amylin Agonists Market, By Region, From 2021 to 2026 (USD Million)
  15. North America GLP-1 Agonists & Analogs Market, By Region, From 2021 to 2026 (USD Million)
  16. North America  Biguanides Market, By Region, From 2021 to 2026 (USD Million)
  17. North America Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Alpha-Glucosidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  20. North America Glinides or Meglitinides ! Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Thiazolidinediones or Glitazones or TZDs Market, By Region, From 2021 to 2026 (USD Million)
  22. United States Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  23. Canada Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  24. Europe Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  25. Europe Sulphonylureas Market, By Region, From 2021 to 2026 (USD Million)
  26. Europe Amylin Agonists Market, By Region, From 2021 to 2026 (USD Million)
  27. Europe GLP-1 Agonists & Analogs Market, By Region, From 2021 to 2026 (USD Million)
  28. Europe  Biguanides Market, By Region, From 2021 to 2026 (USD Million)
  29. Europe Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  30. Europe Alpha-Glucosidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  31. Europe Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  32. Europe Glinides or Meglitinides ! Market, By Region, From 2021 to 2026 (USD Million)
  33. Europe Thiazolidinediones or Glitazones or TZDs Market, By Region, From 2021 to 2026 (USD Million)
  34. U.K. Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  35. Germany Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  36. France Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  37. Italy Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  38. Spain Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  39. Asia Pacific Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  40. Asia Pacific Sulphonylureas Market, By Region, From 2021 to 2026 (USD Million)
  41. Asia Pacific Amylin Agonists Market, By Region, From 2021 to 2026 (USD Million)
  42. Asia Pacific GLP-1 Agonists & Analogs Market, By Region, From 2021 to 2026 (USD Million)
  43. Asia Pacific  Biguanides Market, By Region, From 2021 to 2026 (USD Million)
  44. Asia Pacific Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  45. Asia Pacific Alpha-Glucosidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  46. Asia Pacific Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  47. Asia Pacific Glinides or Meglitinides ! Market, By Region, From 2021 to 2026 (USD Million)
  48. Asia Pacific Thiazolidinediones or Glitazones or TZDs Market, By Region, From 2021 to 2026 (USD Million)
  49. Japan Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  50. China Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  51. India Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  52. Australia Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  53. South Korea Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  54. Latin America Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  55. Latin America Sulphonylureas Market, By Region, From 2021 to 2026 (USD Million)
  56. Latin America Amylin Agonists Market, By Region, From 2021 to 2026 (USD Million)
  57. Latin America GLP-1 Agonists & Analogs Market, By Region, From 2021 to 2026 (USD Million)
  58. Latin America  Biguanides Market, By Region, From 2021 to 2026 (USD Million)
  59. Latin America Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  60. Latin America Alpha-Glucosidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  61. Latin America Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  62. Latin America Glinides or Meglitinides ! Market, By Region, From 2021 to 2026 (USD Million)
  63. Latin America Thiazolidinediones or Glitazones or TZDs Market, By Region, From 2021 to 2026 (USD Million)
  64. Brazil Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  65. Argentina Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  66. Mexico Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  67. Rest of Latin America Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  68. Middle East and Africa Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  69. Middle East and Africa Sulphonylureas Market, By Region, From 2021 to 2026 (USD Million)
  70. Middle East and Africa Amylin Agonists Market, By Region, From 2021 to 2026 (USD Million)
  71. Middle East and Africa GLP-1 Agonists & Analogs Market, By Region, From 2021 to 2026 (USD Million)
  72. Middle East and Africa Biguanides Market, By Region, From 2021 to 2026 (USD Million)
  73. Middle East and Africa Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  74. Middle East and Africa Alpha-Glucosidase Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  75. Middle East and Africa Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  76. Middle East and Africa Glinides or Meglitinides! Market, By Region, From 2021 to 2026 (USD Million)
  77. Middle East and Africa Thiazolidinediones or Glitazones or TZDs Market, By Region, From 2021 to 2026 (USD Million)
  78. Middle East Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)
  79. Africa Non-Insulin Diabetes Therapy Market, By Drug Type, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample